258 related articles for article (PubMed ID: 25038326)
1. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
Bol KF; Mensink HW; Aarntzen EH; Schreibelt G; Keunen JE; Coulie PG; de Klein A; Punt CJ; Paridaens D; Figdor CG; de Vries IJ
Am J Ophthalmol; 2014 Nov; 158(5):939-47. PubMed ID: 25038326
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol KF; van den Bosch T; Schreibelt G; Mensink HW; Keunen JE; Kiliç E; Japing WJ; Geul KW; Westdorp H; Boudewijns S; Croockewit SA; van Rossum MM; de Goede AL; Naus NC; van der Graaf WT; Gerritsen WR; de Klein A; Punt CJ; Figdor CG; Cohen VM; Paridaens D; de Vries IJ
Ophthalmology; 2016 Oct; 123(10):2265-7. PubMed ID: 27476772
[No Abstract] [Full Text] [Related]
3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
4. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
5. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma].
Schuler-Thurner B; Bartz-Schmidt KU; Bornfeld N; Cursiefen C; Fuisting B; Grisanti S; Heindl LM; Holbach L; Keserü M; Knorr H; Koch K; Kruse F; Meiller R; Metz C; Meyer-ter-Vehn T; Much M; Reinsberg M; Schliep S; Seitz B; Schuler G; Süsskind D; Viestenz A; Wagenfeld L; Zeschnigk M
Ophthalmologe; 2015 Dec; 112(12):1017-21. PubMed ID: 26602097
[TBL] [Abstract][Full Text] [Related]
7. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of treatments for metastatic uveal melanoma.
Augsburger JJ; Corrêa ZM; Shaikh AH
Am J Ophthalmol; 2009 Jul; 148(1):119-27. PubMed ID: 19375060
[TBL] [Abstract][Full Text] [Related]
9. Variates of survival in metastatic uveal melanoma.
Rietschel P; Panageas KS; Hanlon C; Patel A; Abramson DH; Chapman PB
J Clin Oncol; 2005 Nov; 23(31):8076-80. PubMed ID: 16258106
[TBL] [Abstract][Full Text] [Related]
10. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
de Vries IJ; Bernsen MR; Lesterhuis WJ; Scharenborg NM; Strijk SP; Gerritsen MJ; Ruiter DJ; Figdor CG; Punt CJ; Adema GJ
J Clin Oncol; 2005 Aug; 23(24):5779-87. PubMed ID: 16110035
[TBL] [Abstract][Full Text] [Related]
11. Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
Boudewijns S; Westdorp H; Koornstra RH; Aarntzen EH; Schreibelt G; Creemers JH; Punt CJ; Figdor CG; de Vries IJ; Gerritsen WR; Bol KF
J Immunother; 2016; 39(6):241-8. PubMed ID: 27227325
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
13. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.
Gonsalves CF; Eschelman DJ; Sullivan KL; Anne PR; Doyle L; Sato T
AJR Am J Roentgenol; 2011 Feb; 196(2):468-73. PubMed ID: 21257902
[TBL] [Abstract][Full Text] [Related]
15. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Schreibelt G; Bol KF; Westdorp H; Wimmers F; Aarntzen EH; Duiveman-de Boer T; van de Rakt MW; Scharenborg NM; de Boer AJ; Pots JM; Olde Nordkamp MA; van Oorschot TG; Tel J; Winkels G; Petry K; Blokx WA; van Rossum MM; Welzen ME; Mus RD; Croockewit SA; Koornstra RH; Jacobs JF; Kelderman S; Blank CU; Gerritsen WR; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2016 May; 22(9):2155-66. PubMed ID: 26712687
[TBL] [Abstract][Full Text] [Related]
16. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
17. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
18. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
19. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
[TBL] [Abstract][Full Text] [Related]
20. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
